Nonmetastatic castration-resistant prostate cancer: current challenges and trends
A Figueiredo, L Costa, MJ Maurício, L Figueira… - Clinical Drug …, 2022 - Springer
Prostate carcinoma is a highly prevalent biologically and clinically diverse disease,
generally associated with a consistent elevation of prostate-specific antigen levels …
generally associated with a consistent elevation of prostate-specific antigen levels …
[HTML][HTML] Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
Nonmetastatic castration-resistant prostate cancer (nmCRPC)-defined as prostate-specific
antigen (PSA)> 2 ng/mL, testosterone castration levels< 1.7 nm/L, and the absence of …
antigen (PSA)> 2 ng/mL, testosterone castration levels< 1.7 nm/L, and the absence of …
Non-metastatic castration-resistant prostate cancer: current status and future directions
Introduction The emergence of novel hormonal therapies and the increase availability of
sensitive next-generation imaging techniques has significantly changed the management of …
sensitive next-generation imaging techniques has significantly changed the management of …
[HTML][HTML] Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer
Prostate cancer remains a significant cause of cancer-related deaths in men in the United
States. Significant advances in the treatment of metastatic castration-resistant prostate …
States. Significant advances in the treatment of metastatic castration-resistant prostate …
Treatment of nonmetastatic castration-resistant prostate cancer
Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a
heterogeneous population with regard to risk of progression to metastatic disease …
heterogeneous population with regard to risk of progression to metastatic disease …
Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment
A Anantharaman, EJ Small - Expert review of anticancer therapy, 2017 - Taylor & Francis
ABSTRACT Introduction: Prostate cancer (PCa) is currently the second most common
cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is …
cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is …
Update on options for treatment of metastatic castration-resistant prostate cancer
P Vishnu, WW Tan - OncoTargets and Therapy, 2010 - Taylor & Francis
Background: Prostate cancer is one of the most common cancers in men in US and
European countries. Despite having a favorable prognosis, the incidence of incurable …
European countries. Despite having a favorable prognosis, the incidence of incurable …
Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?
I Heidegger, MP Brandt, MM Heck - Urologic Oncology: Seminars and …, 2020 - Elsevier
Lately the development of 3 novel second-generation androgen receptor antagonists
(enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of …
(enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of …
New treatment options in castration-resistant prostate cancer
AJ Armstrong - Journal of the National Comprehensive Cancer …, 2015 - jnccn.org
Most of the updates in the 2015 NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines) for Prostate Cancer center on the systemic therapy front, with a host of newer …
Guidelines) for Prostate Cancer center on the systemic therapy front, with a host of newer …
Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
Prostate cancer (PCa) continues to be one of the leading causes of cancer-related deaths in
men worldwide (1). Localized PCa responds well with the initial treatment such as surgery …
men worldwide (1). Localized PCa responds well with the initial treatment such as surgery …